Global Clinical Oncology Next Generation Sequencing (NGS) Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 156178
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 137
  • list Pharmaceuticals and Healthcare

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.

Scope of the Report:

This report studies the Clinical Oncology Next Generation Sequencing (NGS) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Clinical Oncology Next Generation Sequencing (NGS) market by product type and applications/end industries.

The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.

The global Clinical Oncology Next Generation Sequencing (NGS) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Clinical Oncology Next Generation Sequencing (NGS).

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Illumina

Roche

Agilent Technologies

Knome

Genomatix Software

GATC Biotech

Oxford Nanopore Technologies

Macrogen

Life Technologies

DNASTAR

Exosome Diagnostics

Biomatters

CLC Bio

BGI

Qiagen

Perkin Elmer

Pacific Bioscience

Partek

GnuBIO

Foundation Medicine

Paradigm

Caris Life Sciences

Myriad Genetics

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

NGS Pre-Sequencing

Sequencing

NGS Data Analysis

Primary, Secondary & Tertiary Data Analysis

Market Segment by Applications, can be divided into

Academic & Clinical Research

Hospitals & Clinics

Pharma & Biotech Entities

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Clinical Oncology Next Generation Sequencing (NGS) Market Overview

1.1 Product Overview and Scope of Clinical Oncology Next Generation Sequencing (NGS)

1.2 Classification of Clinical Oncology Next Generation Sequencing (NGS) by Types

1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Comparison by Types (2017-2023)

1.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Types in 2017

1.2.3 NGS Pre-Sequencing

1.2.4 Sequencing

1.2.5 NGS Data Analysis

1.2.6 Primary, Secondary & Tertiary Data Analysis

1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application

1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Academic & Clinical Research

1.3.3 Hospitals & Clinics

1.3.4 Pharma & Biotech Entities

1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Regions

1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2013-2023)

1.5 Global Market Size of Clinical Oncology Next Generation Sequencing (NGS) (2013-2023)

2 Manufacturers Profiles

2.1 Illumina

2.1.1 Business Overview

2.1.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.2 Roche

2.2.1 Business Overview

2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.3 Agilent Technologies

2.3.1 Business Overview

2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.4 Knome

2.4.1 Business Overview

2.4.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.5 Genomatix Software

2.5.1 Business Overview

2.5.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.6 GATC Biotech

2.6.1 Business Overview

2.6.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.7 Oxford Nanopore Technologies

2.7.1 Business Overview

2.7.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.8 Macrogen

2.8.1 Business Overview

2.8.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.9 Life Technologies

2.9.1 Business Overview

2.9.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.10 DNASTAR

2.10.1 Business Overview

2.10.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.11 Exosome Diagnostics

2.11.1 Business Overview

2.11.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.12 Biomatters

2.12.1 Business Overview

2.12.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.13 CLC Bio

2.13.1 Business Overview

2.13.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.14 BGI

2.14.1 Business Overview

2.14.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.15 Qiagen

2.15.1 Business Overview

2.15.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.15.2.1 Product A

2.15.2.2 Product B

2.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.16 Perkin Elmer

2.16.1 Business Overview

2.16.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.16.2.1 Product A

2.16.2.2 Product B

2.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.17 Pacific Bioscience

2.17.1 Business Overview

2.17.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.17.2.1 Product A

2.17.2.2 Product B

2.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.18 Partek

2.18.1 Business Overview

2.18.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.18.2.1 Product A

2.18.2.2 Product B

2.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.19 GnuBIO

2.19.1 Business Overview

2.19.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.19.2.1 Product A

2.19.2.2 Product B

2.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.20 Foundation Medicine

2.20.1 Business Overview

2.20.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.20.2.1 Product A

2.20.2.2 Product B

2.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.21 Paradigm

2.21.1 Business Overview

2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.21.2.1 Product A

2.21.2.2 Product B

2.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.22 Caris Life Sciences

2.22.1 Business Overview

2.22.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.22.2.1 Product A

2.22.2.2 Product B

2.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

2.23 Myriad Genetics

2.23.1 Business Overview

2.23.2 Clinical Oncology Next Generation Sequencing (NGS) Type and Applications

2.23.2.1 Product A

2.23.2.2 Product B

2.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2016-2017)

3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Competition, by Players

3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share

3.2.2 Top 10 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share

3.3 Market Competition Trend

4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions

4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Regions

4.2 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

4.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

4.5 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

5 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries

5.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2013-2018)

5.2 USA Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

5.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

5.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

6 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries

6.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2013-2018)

6.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

6.3 UK Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

6.4 France Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

6.5 Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

6.6 Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries

7.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2013-2018)

7.2 China Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

7.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

7.4 Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

7.5 India Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

8 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries

8.1 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2013-2018)

8.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

8.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

8.4 Colombia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Clinical Oncology Next Generation Sequencing (NGS) by Countries

9.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2013-2018)

9.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

9.3 UAE Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

9.4 Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

9.5 Nigeria Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

9.6 South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2013-2018)

10 Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment by Type

10.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Type (2013-2018)

10.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2018-2023)

10.3 NGS Pre-Sequencing Revenue Growth Rate (2013-2023)

10.4 Sequencing Revenue Growth Rate (2013-2023)

10.5 NGS Data Analysis Revenue Growth Rate (2013-2023)

10.6 Primary, Secondary & Tertiary Data Analysis Revenue Growth Rate (2013-2023)

11 Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment by Application

11.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2013-2018)

11.2 Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2018-2023)

11.3 Academic & Clinical Research Revenue Growth (2013-2018)

11.4 Hospitals & Clinics Revenue Growth (2013-2018)

11.5 Pharma & Biotech Entities Revenue Growth (2013-2018)

12 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast (2018-2023)

12.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast (2018-2023)

12.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Regions (2018-2023)

12.3 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2018-2023)

12.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2018-2023)

12.6 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Clinical Oncology Next Generation Sequencing (NGS) Picture

Table Product Specifications of Clinical Oncology Next Generation Sequencing (NGS)

Table Global Clinical O

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery